Inclusion criteria :

          -  Patients must have a known diagnosis of either unresectable hepatocellular carcinoma
             (HCC), platinum-refractory recurrent/metastatic squamous cell carcinoma of the head
             and neck (SCCHN), platinum-resistant/refractory epithelial ovarian cancer (EOC) with
             evidence of measurable disease or recurrent glioblastoma multiforme (GBM).

          -  ≥18 years of age.

          -  For patients with HCC: Documentation of progressive disease (PD) during or after
             treatment with either sorafenib or lenvatinib, or intolerance to the therapy.

          -  For patients with SCCHN: Received and failed up to 2 lines of prior systemic
             anti-cancer therapy with documentation of tumor recurrence or PD within 6 months of
             last platinum-based therapy in primary, recurrent, or metastatic setting.

          -  For patients with EOC: Received up to 3 lines of prior platinum-containing therapy
             when the disease was platinum-sensitive, and the patients should not have received any
             systemic therapy for platinum-resistant/refractory disease. specific to France only:
             Documentation of PD on or after 1 line of anti-cancer therapy for platinum
             resistant/refractory disease (unless patients are ineligible or intolerant to standard
             of care for platinum-resistant/refractory disease).

          -  For patients with GBM: Documentation of PD or first recurrence during or after
             temozolomide maintenance therapy for newly diagnosed GBM treated with 1st line
             radiotherapy plus concurrent temozolomide.

        Exclusion criteria:

          -  Prior exposure to agent that blocks CD38 or participation in clinical studies with
             isatuximab.

          -  For patients with HCC, SCCHN, EOC or GBM prior exposure to any agent (approved or
             investigational) that blocks the PD-1/PD-L1 pathway.

          -  Evidence of other immune related disease /conditions.

          -  History of non-infectious pneumonitis requiring steroids or current pneumonitis;
             history of the thoracic radiation.

          -  Has received a live-virus vaccination within 28 days of planned treatment start.
             Seasonal flu vaccines that do not contain live virus are permitted.

          -  Prior solid organ or bone marrow transplantation.

          -  Eastern Cooperative Oncology Group performance status (PS) ≥2 for patients with HCC,
             SCCHN or EOC or Karnofsky performance score ≤ 70 for patients with GBM.

          -  Poor bone marrow reserve.

          -  Poor organ function.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.